Your browser doesn't support javascript.
loading
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.
McKenna, Marshall; Epperla, Narendranath; Ghobadi, Armin; Liu, Jieqi; Lazaryan, Aleksandr; Ibrahim, Uroosa; Jacobson, Caron A; Naik, Seema G; Nastoupil, Loretta; Chowdhury, Sayan Mullick; Voorhees, Timothy J; Jacobs, Miriam T; Farooq, Umar; Osman, Keren; Olszewski, Adam J; Ahmed, Sairah; Evens, Andrew M.
Affiliation
  • McKenna M; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Epperla N; Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Ghobadi A; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Liu J; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Lazaryan A; Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA.
  • Ibrahim U; Department of Hematology and Oncology, Bone Marrow Transplantation and Cellular Therapy Program, Mount Sinai Hospital, New York, New York, USA.
  • Jacobson CA; Division of Hematologic Malignancies, Harvard Medical School, Dana Faber Cancer Institute, Boston, Massachusetts, USA.
  • Naik SG; Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA.
  • Nastoupil L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chowdhury SM; Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Voorhees TJ; Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Jacobs MT; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Farooq U; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospital and Clinics, Iowa City, Iowa, USA.
  • Osman K; Department of Hematology and Oncology, Bone Marrow Transplantation and Cellular Therapy Program, Mount Sinai Hospital, New York, New York, USA.
  • Olszewski AJ; Lifespan Cancer Institute, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Evens AM; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Br J Haematol ; 202(2): 248-255, 2023 07.
Article in En | MEDLINE | ID: mdl-37129856
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organ Transplantation / Receptors, Chimeric Antigen / Lymphoproliferative Disorders Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Br J Haematol Year: 2023 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organ Transplantation / Receptors, Chimeric Antigen / Lymphoproliferative Disorders Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Br J Haematol Year: 2023 Type: Article Affiliation country: United States